Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Zhu, Hai-Dong; Li, Hai-Liang; Huang, Ming-Sheng; Yang, Wei-Zhu; Yin, Guo-Wen; Zhong, Bin-Yan; Sun, Jun-Hui; Jin, Zhi-Cheng; Chen, Jian-Jian; Ge, Nai-Jian; Ding, Wen-Bin; Li, Wen-Hui; Huang, Jin-Hua; Mu, Wei; Gu, Shan-Zhi; Li, Jia-Ping; Zhao, Hui; Wen, Shu-Wei; Lei, Yan-Ming; Song, Yu-Sheng; Yuan, Chun-Wang; Wang, Wei-Dong; Huang, Ming; Zhao, Wei; Wu, Jian-Bing; Wang, Song; Zhu, Xu; Han, Jian-Jun; Ren, Wei-Xin; Lu, Zai-Ming; Xing, Wen-Ge; Fan, Yong; Lin, Hai-Lan; Zhang, Zi-Shu; Xu, Guo-Hui; Hu, Wen-Hao; Tu, Qiang; Su, Hong-Ying; Zheng, Chuan-Sheng; Chen, Yong; Zhao, Xu-Ya; Fang, Zhu-Ting; Wang, Qi; Zhao, Jin-Wei; Xu, Ai-Bing; Xu, Jian; Wu, Qing-Hua; Niu, Huan-Zhang; Wang, Jian; Dai, Feng; Feng, Dui-Ping; Li, Qing-Dong; Shi, Rong-Shu; Li, Jia-Rui; Yang, Guang; Shi, Hai-Bin; Ji, Jian-Song; Liu, Yu-E; Cai, Zheng; Yang, Po; Zhao, Yang; Zhu, Xiao-Li; Lu, Li-Gong; Teng, Gao-Jun; the CHANCE001 Investigators, for

doi:10.1038/s41392-022-01235-0

Public

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Shared by NobleBlocks on Feb 8, 2023 • 12:00 AM UTC

Authors:

Hai-Dong Zhu

Hai-Liang Li

Ming-Sheng Huang

Abstract

Abstract There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE comb...

Discussions